Drug name - Tibsovo
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9850277 | SERVIER | Therapeutically active compositions and their methods of use |
Jan, 2033
(10 years from now) | |
| US9474779 | SERVIER | Therapeutically active compositions and their methods of use |
Aug, 2033
(10 years from now) | |
| CN104136411B | SERVIER | Therapy Active Compound And Using Method Thereof |
Jan, 2032
(9 years from now) | |
| CN106496090A | SERVIER | Therapy Active Compound And Using Method Thereof |
Jan, 2032
(9 years from now) | |
| CN106496090B | SERVIER | Therapeutically Active Compounds And Methods Of Use Thereof |
Jan, 2032
(9 years from now) | |
| CN104136411A | SERVIER | Therapeutically Active Compounds And Methods Of Use Thereof |
Jan, 2032
(9 years from now) | |
| IN338474B | SERVIER | Therapeutically Active Compositions And Their Methods Of Use |
Jan, 2033
(10 years from now) | |
| IN201405986P1 | SERVIER | Therapeutically Active Compounds And Their Methods Of Use |
Jan, 2033
(10 years from now) | |
| EP2804851B1 | SERVIER | Lactam Derivates Useful As Inhibitors Of Mutant Idh1 |
Jan, 2033
(10 years from now) | |
| EP2804851A4 | SERVIER | Therapeutically Active Compounds And Their Methods Of Use |
Jan, 2033
(10 years from now) | |
| EP3447052B1 | SERVIER | Methods Of Preparing New Idh1 Inhibitors |
Jan, 2033
(10 years from now) | |
| EP3447052A1 | SERVIER | Methods Of Preparing New Idh1 Inhibitors |
Jan, 2033
(10 years from now) | |
| EP2804851A1 | SERVIER | Lactam Derivates Useful As Inhibitors Of Mutant Idh1 |
Jan, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10610125 | SERVIER | Methods and compositions for cell-proliferation-related disorders |
Jun, 2030
(7 years from now) | |
| US10717764 | SERVIER | Therapeutically active compounds and their methods of use |
Jan, 2033
(10 years from now) | |
| US10449184 | SERVIER | Pharmaceutical compositions of therapeutically active compounds |
Mar, 2035
(12 years from now) | |
| US10799490 | SERVIER | Pharmaceutical compositions of therapeutically active compounds |
Mar, 2035
(12 years from now) | |
| US9968595 | SERVIER | Pharmaceutical compositions of therapeutically active compounds |
Mar, 2035
(12 years from now) | |
| US10980788 | SERVIER | Therapy for treating malignancies |
Jun, 2039
(16 years from now) | |
Drugs and Companies using IVOSIDENIB ingredient
Treatment: A method of treating a cancer characterized by an idh1 mutation where the cancer is relapsed or refractory acute myeloid leukemia (aml) and where the mutant idh1 has the ability to convert alpha-ketoglutarate into 2-hydroxyglutarate (2-hg); a method of treating a cancer characterized by an idh1 mutation where the cancer is newly diagnosed acute myeloid leukemia (aml) and where the mutant idh1 has the ability to convert alpha-ketoglutarate into 2-hydroxyglutarate (2-hg); A method of treating previously treated, locally advanced or metastatic cholangiocarcinoma characterized by an idh1 mutation; A method of treating acute myelogenous leukemia (aml) in a subject by administering a pharmaceutical composition where the aml is characterized by the presence of a mutant allele of idh1 and the aml is newly diagnosed; a method of treating acute myelogenous leukemia (aml) in a subject by administering a pharmaceutical composition where the aml is characterized by the presence of a mutant allele of idh1 and where the aml is relapsed/refractory; A method of treating a cancer characterized by an idh1 mutation where the cancer is newly diagnosed acute myeloid leukemia (aml); a method of treating a cancer characterized by an idh1 mutation where the cancer is relapsed or refractory acute myeloid leukemia (aml); treatment of acute myeloid leukemia (aml) with an idh1 mutation; A method of treating previously treated, locally advanced or metastatic cholangiocarcinoma characterized by the presence of a mutant allele of idh1 by administering a once daily 500 mg oral dose to a subject that has not ingested a high-fat meal; treating newly diagnosed acute myelogenous leukemia (aml) characterized by the presence of a mutant allele of idh1 by administering a once daily 500 mg oral dose to a subject that has not ingested a high-fat meal; treating relapsed/refractory acute myelogenous leukemia (aml) characterized by the presence of a mutant allele of idh1 by administering a once daily 500 mg oral dose to a subject that has not ingested a high-fat meal
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 250MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.